RELAY THERAPEUTICS Reports Second Quarter Fiscal Year 2023 Earnings Results on August 8 2023

August 13, 2023

🌥️Earnings Overview

RELAY THERAPEUTICS ($NASDAQ:RLAY) announced their financial results for the second quarter of 2023, ending June 30, on August 8. Their total revenue was USD 0.1 million, a 66.7% decrease compared to the same period in the previous year. Net income was noted at USD -98.5 million, compared to a net loss of USD -76.8 million in the year before.

Share Price

On Tuesday, August 8, 2023, RELAY THERAPEUTICS reported their second quarter fiscal year 2023 earnings results, and the stock opened at $10.5 and closed at $11.2. This was a 7.7% rise from the previous closing price of $10.4, and a strong sign of investor confidence in the company. RELAY THERAPEUTICS is a biopharmaceutical company that develops treatments for oncology and cancer-related diseases. Throughout the quarter, the company saw steady growth, and their earnings report is a testament to their dedication and continuing efforts to make breakthroughs in cancer treatments and therapies.

This strong performance has put RELAY THERAPEUTICS in a strong position to continue to invest in research and development, giving them a platform to further their groundbreaking work in the field of oncology and cancer-related therapies. Overall, the strong performance by RELAY THERAPEUTICS in the second quarter of fiscal year 2023 has given investors and analysts confidence in the company’s future prospects. With an increased ability to invest in research and development, the company is set up for continued success in the coming quarters. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Relay Therapeutics. More…

    Total Revenues Net Income Net Margin
    0.94 -344.42 -37670.5%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Relay Therapeutics. More…

    Operations Investing Financing
    -258.95 6.84 290.41
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Relay Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    962.02 151.9 6.66
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Relay Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -39958.3%
    FCF Margin ROE ROA
    -28321.0% -27.8% -24.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    We at GoodWhale have conducted an analysis of RELAY THERAPEUTICS‘s wellbeing. Our Risk Rating system has concluded that RELAY THERAPEUTICS is a medium risk investment in terms of financial and business aspects. Our team of financial experts have detected two risk warnings in the balance sheet and cash flow statement of RELAY THERAPEUTICS. If you would like to find out more about these risks, please become a registered user on our site. We provide detailed information on RELAY THERAPEUTICS that can help inform your investment decisions. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis




  • Peers

    The company uses artificial intelligence to design and develop small molecule therapeutics for cancer patients. Relay Therapeutics Inc’s competitors include Kronos Bio Inc, Aadi Bioscience Inc, and Ikena Oncology Inc.

    – Kronos Bio Inc ($NASDAQ:KRON)

    Kronos Bio Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation cancer therapies. The company’s lead product candidate is entospletinib, a selective inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) family of proteins. Kronos Bio Inc has a market cap of 146.46M as of 2022, a Return on Equity of -33.99%. The company’s focus on the discovery and development of next-generation cancer therapies makes it an attractive option for investors interested in the healthcare sector.

    – Aadi Bioscience Inc ($NASDAQ:AADI)

    Aadi Bioscience Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of cancer. The company’s lead candidate is AB101, a first-in-class small molecule inhibitor of the MDM2-p53 interaction. AB101 is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors. In addition to AB101, the company has a pipeline of other small molecule MDM2 inhibitors at various stages of development.

    Aadi Bioscience Inc has a market cap of 305.67M as of 2022. The company’s return on equity for the same period is -72.24%. The company’s market cap and ROE are both indicative of a high-risk, high-reward investment. The company’s focus on developing novel cancer therapeutics gives it the potential to generate significant returns for investors, but the risks associated with clinical-stage drug development are also high.

    – Ikena Oncology Inc ($NASDAQ:IKNA)

    Ikena Oncology Inc is a clinical stage biopharmaceutical company, developing cancer therapies. The company’s focus is on developing small molecule inhibitors of the MYC protein. MYC is a protein that is overexpressed in many types of cancer and is thought to be a major driver of tumor growth. Ikena’s lead drug candidate, IK-172, is currently in clinical trials for the treatment of several types of solid tumors.

    Ikena has a market cap of 92.44M as of 2022 and a Return on Equity of -16.89%. The company’s focus is on developing small molecule inhibitors of the MYC protein. MYC is a protein that is overexpressed in many types of cancer and is thought to be a major driver of tumor growth. Ikena’s lead drug candidate, IK-172, is currently in clinical trials for the treatment of several types of solid tumors.

    Summary

    Investors analyzing Relay Therapeutics saw a decline in revenue for the second quarter of fiscal year 2023, totaling USD 0.1 million; a decrease of 66.7% compared to the same period in the previous year. Net income was reported at USD -98.5 million, a deterioration from the net loss of USD -76.8 million in the previous year. Despite the bleak financials, the stock price moved up on the same day, indicating that the market may be looking to the future of Relay Therapeutics and optimistic that the company will be able to turn its performance around. Investors should carefully consider the risks associated with this stock, since poor performance in the past could lead to further losses in the future.

    Recent Posts

    Leave a Comment